Does Recombinant FSH (Gonal-F) Compared to Human Menopausal Gonadotropin (hMG) Affect Telomere Length of Cumulus Cells During Follicle Growth and Impact Blastocyst Quality?

What this Trial Is About

Researchers are studying whether two different fertility medications, recombinant follicle-stimulating hormone (rFSH, Gonal-F4) and human menopausal gonadotropin (hMG, Menopur4), affect the length of telomeres in cumulus cells during egg development and how this might impact embryo quality. This observational, randomized, open-label, cross-over study focuses on women who respond normally to ovarian stimulation and aims to understand differences in embryo development related to these medications. Participants will undergo two ovarian stimulation cycles, each using either Gonal-F or hMG, with initial doses based on ovarian reserve and identical starting dosages for both cycles. Dose adjustments may begin on day 6, with a fixed antagonist from day 5, and final egg maturation triggered by a dual trigger of 2,500 IU urinary hCG and 0.3 mg Decapeptyl. The study compares effects within the same patient across both stimulation types. During the study, hormonal analysis and telomere length measurement in cumulus cells will be performed, along with assessments of embryo quality markers such as morphokinetics development, euploidy, and mitochondrial status of blastocysts. The primary outcome is the telomere length difference between the two stimulation cycles within the same woman, measured over approximately 12 weeks. Participants will be closely monitored throughout the process to evaluate these biological markers and embryo development outcomes.

Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?